Scholar Rock Holding Corp (NASDAQ:SRRK) is set to release its Q4 2024 earnings on Feb 27, 2025. The consensus estimate for Q4 ...
We recently published a list of 10 Oversold Biotech Stocks to Buy Now. In this article, we are going to take a look at where ...
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal ...
Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on Scholar Rock Holding (SRRK – Research Report) today. The company’s ...
In a regulatory filing, Scholar Rock ( SRRK) CEO Jay Backstrom disclosed the sale of 18,372 common shares of the company on February 18 at a price of $36.829 per share. Published first on TheFly – the ...
Scholar Rock said in a conference call late Monday that it plans to initiate a study for the treatment for patients under 2 ...
The last time I wrote about Scholar Rock (NASDAQ:SRRK) it was with respect to a Seeking Alpha article entitled as "Scholar Rock: SMA Program Strides Forward With Positive Clinical Data".
Shares of Scholar Rock Holding Co. (NASDAQ:SRRK – Get Free Report) have been assigned a consensus rating of “Buy” from the ...
Scholar Rock Sets Sights on $2 Billion Apitegromab Revenue Amid Spinal Muscular Atrophy Market Growth Scholar Rock aims for a 2025 launch of apitegromab in SMA, expecting $2 billion in global ...
Scholar Rock (NASDAQ: SRRK; the "Company"), a late-stage biopharmaceutical company focused on advancing innovative treatments ...